Albany Molecular Research acquires 100% stake in Excelsyn - MarketLine Financial Deals

Albany Molecular Research acquires 100% stake in Excelsyn

Albany Molecular Research acquires 100% stake in Excelsyn - MarketLine Financial Deals
Albany Molecular Research acquires 100% stake in Excelsyn
Published Feb 17, 2010
3 pages — Published Feb 17, 2010
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Albany Molecular Research, Inc. (AMRI) has acquired all of the outstanding shares of Excelsyn Limited.

  
Source:
Document ID
MA19685_100219
Country
Country
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Albany Molecular Research acquires 100% stake in Excelsyn" Feb 17, 2010. Alacra Store. Dec 10, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Albany-Molecular-Research-acquires-100-stake-in-Excelsyn-2052-24319>
  
APA:
MarketLine Financial Deals. (2010). Albany Molecular Research acquires 100% stake in Excelsyn Feb 17, 2010. New York, NY: Alacra Store. Retrieved Dec 10, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Albany-Molecular-Research-acquires-100-stake-in-Excelsyn-2052-24319>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.